Time Commitment: 5 hours over 56 days
Target Professions: DO, MD, Nurse, Nurse Practitioner, Physician Assistant
Target Specialties: Hematology/Oncology
Credits Available: 5.0 AMA PRA Category 1 Credit

Multiple myeloma (MM) is a clonal plasma cell disorder arising from the bone marrow and is the second most common hematologic malignancy in the United States (US), with an incidence of approximately 35,000 new cases per year. While progression-free survival (PFS) benefit is often seen with MM therapeutics, overall survival (OS) benefit is rarely seen with novel therapies, and improvements in PFS are still associated with adverse events and long-term disease refractoriness. Over the past few decades, rigorous pre-clinical and clinical research has led to the discovery of novel therapies that have dramatically changed the treatment landscape of MM in the frontline as well as in the relapsed/refractory setting. Despite implementing multimodal approaches to treat MM, the major challenge remains that the vast majority of patients eventually relapse and become refractory to multiple drug classes. Additionally, patients require continuous treatment throughout the disease course, which can negatively affect their quality of life due to potential therapy-related side effects. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with multiple myeloma.

CME/CE Accreditation Information

Self Study

Live Group Discussions

  • Live Group Discussion 1

    During this session, we will review the self-study modules and discuss approaches to treatment that offer optimal care to patients with relapsed refractory multiple myeloma.

  • Live Group Discussion 2

    During this session, we will review the patient case and discuss treatment plans. Additionally, we will share our action plans and how this CME activity will shape our practice regarding patient care.

Group Tasks

  • Multiple Myeloma Group Challenge: Jeffery's Case

    Meet Jeffery, a 59-year-old man with a history of IgG kappa multiple myeloma.

My Action Plans

  • Your Action Plan In Heavily Relapsed Multiple Myeloma

    In light of the information reviewed and discussed during this program, please share an action plan that you will implement to improve the diagnosis and management for your patients with relapsed refractory multiple myeloma.

Interested in becoming a Group Leader?

Experts in the management of patients with multiple myeloma, including physicians and advanced practice providers. Apply Now

You cannot sign up as a Group Member because there are no groups available or because you are already signed up.